Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CohBar Inc
CWBR
Healthcare
Biotechnology
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to...
identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:CWBR)
New Post
View:
Posts & Comments
Threaded Posts
(2247)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 10, 2021 4:12pm
Second Quarter 2021 Financial Results & Provides Update
MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and
...more
(2247)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 10, 2021 4:09pm
Positive Topline Results from the Phase 1a/1b Study
CB4211 was well-tolerated and appeared safe with no serious adverse events Robust reductions in ALT and AST Reduction in glucose and trend towards body weight reduction Company to host
...more
(13)
•••
decentstock
X
View Profile
View Bullboard History
Post by
decentstock
on Feb 16, 2021 1:44pm
BIO Conference going on-CWBR
MENLO PARK, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and
...more
(13)
•••
decentstock
X
View Profile
View Bullboard History
Post by
decentstock
on Jan 27, 2021 1:10pm
CWBR-3rd Annual Longevity Therapeutics Conference -Jan 28th
CohBar to Present at the 3rd Annual Longevity Therapeutics Conference CWBR | 7 days ago MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CohBar,
...more
(1)
•••
GreenDream
X
View Profile
View Bullboard History
Post by
GreenDream
on Sep 27, 2018 2:02pm
CohBar Engages LifeSci Advisors as Investor Relations
GLOBENEWSWIRE CohBar Engages LifeSci Advisors as Investor Relations Partner 09/25/2018 9:00:00 AM MENLO PARK, Calif., Sept. 25, 2018 (GLOBE
...more
(0)
•••
Oberon6
X
View Profile
View Bullboard History
Comment by
Oberon6
on Oct 18, 2017 12:00am
RE:RE:RE:going going gone
If only I had a crystal ball, unfortunatly I've only got an opinion. They've kept a low profile and I'd say that this up coming confrence will generate a lot of exposure to the right
...more
(1588)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Oct 17, 2017 6:32pm
RE:RE:going going gone
That's true -- it was $1.75 on July 4th and is now $6. Question is -- where does it go from here after that big run?
(29)
•••
thedave2006
X
View Profile
View Bullboard History
Post by
thedave2006
on Oct 17, 2017 6:30pm
Michael Smedley BNN top pick today
.
(0)
•••
Oberon6
X
View Profile
View Bullboard History
Comment by
Oberon6
on Oct 11, 2017 11:52pm
RE:going going gone
I'm afraid you do not have a future in fortune telling.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >